Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study

帕唑帕尼 医学 中性粒细胞减少症 软组织肉瘤 危险系数 内科学 阿霉素 耐受性 发热性中性粒细胞减少症 肿瘤科 临床终点 肉瘤 外科 癌症 化疗 随机对照试验 置信区间 不利影响 软组织 病理 舒尼替尼
作者
Viktor Grünwald,Annika Karch,Markus K. Schuler,Patrick Schöffski,Hans‐Georg Kopp,Sebastian Bauer,Bernd Kasper,Lars H. Lindner,Jens‐Marcus Chemnitz,Martina Crysandt,Alexander Stein,Björn Steffen,Stephan Richter,Gerlinde Egerer,Philipp Ivanyi,Silke Zimmermann,Xiaofei Liu,Annegret Kunitz
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (30): 3555-3564 被引量:71
标识
DOI:10.1200/jco.20.00714
摘要

PURPOSE Doxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that of doxorubicin in elderly patients with STS and offers superior tolerability for hematologic toxicity. PATIENTS AND METHODS Patients age 60 years or older without previous systemic treatment for progressive advanced or metastatic STS who had Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were included. Treatment consisted of pazopanib 800 mg once per day or doxorubicin 75 mg/m 2 once every 3 weeks (≤ 6 cycles) after being randomly assigned in a 2:1 ratio. Noninferiority was assumed for progression-free survival (PFS), if the upper limit of the 95% CI for the hazard ratio (HR) was less than 1.8. Neutropenia and febrile neutropenia were key secondary end points. The European Organisation for Research and Treatment of Cancer (30-item) Quality of Life Questionnaire and geriatric assessment were used to measure patient-reported outcomes. Cox regression analysis and Kaplan-Meier curves were used for analysis. RESULTS Pazopanib and doxorubicin were given to 81 and 39 patients, respectively. The median age was 71 years (range, 60-88 years). PFS was noninferior (HR, 1.00; 95% CI, 0.65 to 1.53) and the incidence of grade 4 neutropenia and febrile neutropenia favored pazopanib. Objective response rates for pazopanib and doxorubicin were 12.3% and 15.4%, respectively. Overall survival did not differ significantly between arms (HR, 1.08; 95% CI, 0.68 to 1.72; P = .735). Geriatric assessment revealed 2 or more comorbidities in 15.8% of the patients and impairment of activities of daily living in 28.3% of patients. CONCLUSION Pazopanib was noninferior to doxorubicin, rendering pazopanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or older. The distinct adverse event profile may be used to counsel patients and tailor therapy to individual needs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青应助TKTK采纳,获得30
刚刚
Xiaojie完成签到,获得积分10
1秒前
2秒前
Ghost完成签到,获得积分10
2秒前
徐振阳发布了新的文献求助10
2秒前
4秒前
4秒前
独特元蝶发布了新的文献求助10
4秒前
6秒前
7秒前
8秒前
liangye2222发布了新的文献求助10
9秒前
9秒前
小毛驴完成签到,获得积分10
9秒前
10秒前
Huang_being发布了新的文献求助10
11秒前
refraincc发布了新的文献求助10
13秒前
song发布了新的文献求助10
15秒前
量子星尘发布了新的文献求助10
16秒前
Orange应助BeBrave1028采纳,获得10
16秒前
Andrew完成签到,获得积分10
16秒前
17秒前
独特元蝶完成签到,获得积分20
17秒前
醉熏的灵发布了新的文献求助30
17秒前
cyyyyyyyyyy完成签到,获得积分10
19秒前
何1发布了新的文献求助10
19秒前
yang完成签到,获得积分10
20秒前
深情安青应助冬瓜熊采纳,获得10
20秒前
22秒前
cindywu发布了新的文献求助10
22秒前
白先生完成签到 ,获得积分10
23秒前
二哥和他的长毛黄完成签到,获得积分10
24秒前
24秒前
24秒前
科研通AI2S应助refraincc采纳,获得10
25秒前
26秒前
官官发布了新的文献求助10
27秒前
555557应助年轻的烨华采纳,获得10
27秒前
30秒前
hjjjjj1发布了新的文献求助10
30秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988975
求助须知:如何正确求助?哪些是违规求助? 3531316
关于积分的说明 11253424
捐赠科研通 3269917
什么是DOI,文献DOI怎么找? 1804830
邀请新用户注册赠送积分活动 882063
科研通“疑难数据库(出版商)”最低求助积分说明 809068